FdaApplication
BLA 761336
Identifiers
- fda_app_no: BLA761336
Properties
| Property | Value |
|---|---|
| applicant_name | Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc. |
| application_type | BLA |
| approval_date | 2024-04-22 |
Revenue by product
ANKTIVA
| Period | Revenue |
|---|---|
| Q2 2026 | $50.7M |
| Q1 2026 | $44.2M |
| Q3 2024 | $6.0M |
| Q1 2024 | $0.0M† |
| Q4 2023 | $0.1M† |
| Q3 2023 | $0.1M† |
| Q1 2023 | $0.4M† |
| Q4 2022 | $0.1M† |
| Q3 2022 | $0.1M† |
| Q1 2021 | $0.1M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ANKTIVA | nogapendekin alfa inbakicept-pmln | 400MCG/0.4ML | Solution |
1 product